Development and Validation of a Novel LC-MS/MS Method for the Simultaneous Determination of Abemaciclib, Palbociclib, Ribociclib, Anastrozole, Letrozole, and Fulvestrant in Plasma Samples: A Prerequisite for Personalized Breast Cancer Treatment

Palbociclib, ribociclib and abemaciclib were recently approved as chemotherapeutic agents and are currently in the post-marketing surveillance phase. They are used in combination with aromatase inhibitors anastrozole and letrozole or antiestrogen fulvestrant for HR+, HER2− breast cancer treatment. H...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Lu Turković, Luka Bočkor, Oscar Ekpenyong, Tajana Silovski, Mila Lovrić, Slaven Crnković, Biljana Nigović, Miranda Sertić
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2022-05-01
coleção:	Pharmaceuticals
Assuntos:	CDK4/6 inhibitors breast cancer palbociclib ribociclib abemaciclib anastrozole
Acesso em linha:	https://www.mdpi.com/1424-8247/15/5/614
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!